A Novel Agent for a Rare Bone Marrow Disease by JonN | Jan 31, 2012 | 0 comments Advertisement FacebookTwitterLinkedinThe FDA has approved ruxolitinib (Jakafi, Incyte) for myelofibrosis, a rare bone marrow disease. The agent inhibits the JAK1 and JAK2 enzymes, which play a role in blood regulation and immunological functioning. Readings & Resources (click to view) Source: FDA. For more on the approval, visit www.fda.gov/NewsEvents. Submit a Comment Cancel reply Your email address will not be published. Required fields are marked *Comment Name * Email * Website Please enter an answer in digits:2 × five =
